Drug Trial Radar · NCT00866697
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
940
Actual
Start
May 26, 2009
Primary completion
Jul 8, 2012
Study completion Aug 24, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Mar 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
Conditions
- Ovarian Cancer
Interventions
PazopanibDrug
Pazopanib 800 mg tablet daily for 104 weeks (24 months)
PlaceboDrug
Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed Progression-free Survival (PFS)Time frame: From the date of randomization until the date of progression or death due to any cause (median time of follow-up was 17.9 months for pazopanib and 12.3 months for placebo)
Locations
318 sites in 17 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Baldwin Park, California
Novartis Investigative Site
Bellflower, California
Novartis Investigative Site
Duarte, California
Novartis Investigative Site
Fontana, California
Novartis Investigative Site
Hayward, California
Novartis Investigative Site
Irvine, California
Novartis Investigative Site
Long Beach, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Los Angeles, California
Novartis Investigative Site
Oakland, California
Novartis Investigative Site
Ontario, California
Novartis Investigative Site
Orange, California
Novartis Investigative Site
Panorama City, California
Novartis Investigative Site
Riverside, California
Novartis Investigative Site
Roseville, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Diego, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
San Jose, California
Novartis Investigative Site
Santa Clara, California
Novartis Investigative Site
South San Francisco, California
Novartis Investigative Site
Vallejo, California
Novartis Investigative Site
Walnut Creek, California
Novartis Investigative Site
Woodland Hills, California
Novartis Investigative Site
Augusta, Georgia
Novartis Investigative Site
Morristown, New Jersey
Novartis Investigative Site
New York, New York
Novartis Investigative Site
New York, New York
Novartis Investigative Site
The Bronx, New York
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Annandale, Virginia
Novartis Investigative Site
Melbourne, Australia
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Liverpool, New South Wales, Australia
Novartis Investigative Site
Randwick, New South Wales, Australia
Novartis Investigative Site
Waratah, New South Wales, Australia
Showing 40 of 318 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.